ROSSARI, FEDERICO
 Distribuzione geografica
Continente #
NA - Nord America 1.162
AS - Asia 499
EU - Europa 315
SA - Sud America 135
AF - Africa 12
Totale 2.123
Nazione #
US - Stati Uniti d'America 1.129
SG - Singapore 240
IT - Italia 132
BR - Brasile 115
CN - Cina 115
VN - Vietnam 49
DE - Germania 48
HK - Hong Kong 41
GB - Regno Unito 30
CA - Canada 19
NL - Olanda 18
JP - Giappone 16
FR - Francia 15
MX - Messico 13
IN - India 12
PL - Polonia 12
SE - Svezia 12
AR - Argentina 11
RU - Federazione Russa 9
BD - Bangladesh 7
AT - Austria 6
ES - Italia 6
FI - Finlandia 6
LT - Lituania 6
CH - Svizzera 5
ZA - Sudafrica 5
ID - Indonesia 4
PK - Pakistan 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
EG - Egitto 3
IQ - Iraq 3
BE - Belgio 2
CO - Colombia 2
GR - Grecia 2
IE - Irlanda 2
MA - Marocco 2
TR - Turchia 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CL - Cile 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
NP - Nepal 1
PE - Perù 1
RS - Serbia 1
TH - Thailandia 1
UA - Ucraina 1
UY - Uruguay 1
VE - Venezuela 1
Totale 2.123
Città #
Dallas 832
Singapore 144
Ashburn 66
Hong Kong 41
Beijing 37
Milan 32
Los Angeles 29
New York 25
Ho Chi Minh City 21
Munich 18
São Paulo 17
Tokyo 15
Hefei 14
Orem 13
Rome 13
Montreal 12
Poplar 12
Frankfurt am Main 10
Hanoi 10
Manchester 10
Warsaw 10
Shanghai 9
Atlanta 8
Denver 8
London 8
Mexico City 8
Boardman 7
Cesano Boscone 7
Bacoli 6
Berlin 6
Brooklyn 6
Chennai 6
Monza 6
Phoenix 6
Santa Clara 6
Stockholm 6
Biên Hòa 5
Chicago 5
Naples 5
Nuremberg 5
Toronto 5
Boston 4
Helsinki 4
Houston 4
Johannesburg 4
Moscow 4
Querétaro 4
Amsterdam 3
Belo Horizonte 3
Buenos Aires 3
Catania 3
Mumbai 3
Pelotas 3
Porto Alegre 3
Schafisheim 3
Verona 3
Vienna 3
Vilnius 3
Bologna 2
Brussels 2
Carouge 2
Charlotte 2
Cleveland 2
Da Nang 2
Dublin 2
Duque de Caxias 2
Falkenstein 2
Formosa 2
Guangzhou 2
Guarulhos 2
Helena 2
Honolulu 2
Lucca 2
Maceió 2
Marcianise 2
Padua 2
Passo Fundo 2
Pescara 2
Recife 2
Rio de Janeiro 2
Salvador 2
San Jose 2
Santa Cruz 2
Santa Fe 2
Trieste 2
Turku 2
Valmadrera 2
Wroclaw 2
Agadir 1
Alexandria 1
Almirante Tamandaré 1
Alto Paraguai 1
Amontada 1
Amstelveen 1
Anacapri 1
Ankara 1
Annapolis 1
Antakya 1
Araras 1
Athens 1
Totale 1.638
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 388
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 373
Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models 121
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 85
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 81
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 79
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 72
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 58
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 57
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 56
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 54
Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-Tnf: Neutrophil-To-lymphocyte ratio and platelet-To-lymphocyte ratio 52
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 51
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 51
The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia 50
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 50
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 43
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 43
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 43
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 42
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 42
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 41
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 41
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 37
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 34
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 34
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 29
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 22
A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice 20
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 19
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 17
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 15
null 7
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 3
Totale 2.210
Categoria #
all - tutte 5.556
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.556


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 1 0 0 0 0 0
2022/202316 2 3 0 2 2 1 1 0 2 3 0 0
2023/202442 0 1 5 2 5 4 0 0 0 2 8 15
2024/2025273 18 4 3 13 20 19 30 49 21 15 19 62
2025/20261.878 157 443 589 357 253 79 0 0 0 0 0 0
Totale 2.210